Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Authors:
- Beatriz Cirauqui CirauquiBCBeatriz Cirauqui Cirauqui
- Vanesa Quiroga GarcíaVGVanesa Quiroga García
- Clara Lezcano RubioCRClara Lezcano Rubio
- Maria Iciar Pascual MiguelMMMaria Iciar Pascual Miguel
- Laia Capdevila RieraLRLaia Capdevila Riera
- Nuria Pardo ArandaNANuria Pardo Aranda
- Sara Vizcaya MartínSMSara Vizcaya Martín
- Antonio Mariscal MartínezAMAntonio Mariscal Martínez
- Clara Rodríguez CarunchoCCClara Rodríguez Caruncho
- Mireia Margelí VilaMVMireia Margelí Vila
Open Access
- 3 January 2014
- journal article
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 6
Abstract
Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.Keywords
This publication has 16 references indexed in Scilit:
- Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patientsEuropean Journal of Cancer, 2011
- Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer PatientsAnnals of Surgical Oncology, 2011
- Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approvalOncoTargets and Therapy, 2011
- Safety and Efficacy of nab -Paclitaxel in the Treatment of Patients with Breast CancerBreast Cancer: Basic and Clinical Research, 2011
- Photosensitive Rash in Association with Porphyrin Biosynthesis Possibly Induced by Docetaxel and Trastuzumab Therapy in a Patient with Metastatic Breast CarcinomaJapanese Journal of Clinical Oncology, 2010
- Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Cutaneous reaction associated with weekly docetaxel administrationJournal of Oncology Pharmacy Practice, 2008
- Toxicidad cutánea asociada a la administración de paclitaxelFarmacia Hospitalaria, 2008
- Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drugExpert Opinion on Drug Delivery, 2008
- Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2005